H.U. Group Holdings, Inc. (MRCHF)
OTCMKTS
· Delayed Price · Currency is USD
21.20
-0.20 (-0.93%)
At close: May 27, 2025
H.U. Group Holdings Revenue
In the fiscal year ending March 31, 2025, H.U. Group Holdings had annual revenue of 243.03B JPY with 2.56% growth. H.U. Group Holdings had revenue of 60.98B in the quarter ending March 31, 2025, with 2.59% growth.
Revenue
243.03B JPY
Revenue Growth
+2.56%
P/S Ratio
0.74
Revenue / Employee
45.90M JPY
Employees
5,295
Market Cap
1.20B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 243.03B | 6.08B | 2.56% |
Mar 31, 2024 | 236.95B | -23.96B | -9.18% |
Mar 31, 2023 | 260.91B | -12.04B | -4.41% |
Mar 31, 2022 | 272.94B | 49.93B | 22.39% |
Mar 31, 2021 | 223.02B | 34.30B | 18.18% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
American Oncology Network | 1.76B |